Cancer prevention: From 1727 to milestones of the past 100 years

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5269-5284

  Lippman, Scott M ^a   Hawk, Ernest T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANASTROZOLE; BCG VACCINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; DEGUELIN; DUTASTERIDE; EFLORNITHINE; FINASTERIDE; HEPATITIS B VACCINE; INOSITOL; NICOTINE GUM; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; RESVERATROL; RETINOID; RETINOL; ROFECOXIB; SULINDAC; TAMOXIFEN; VARENICLINE; WART VIRUS VACCINE;

ADENOMATOUS POLYP; ANTIANGIOGENIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; COLON ADENOMA; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DNA METHYLATION; FAMILIAL CANCER; GENETIC COUNSELING; GENETIC ENGINEERING; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LEUKOPLAKIA; LIVER CANCER; LUNG CANCER; MOLECULAR BIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OBESITY; OVARIECTOMY; OVARY CANCER; PAPANICOLAOU TEST; POLYPECTOMY; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; SKIN CARCINOGENESIS; SMOKING CESSATION; TOBACCO DEPENDENCE; UTERINE CERVIX CARCINOMA; VAGINAL INTRAEPITHELIAL NEOPLASIA; VITAMIN SUPPLEMENTATION; VULVA CARCINOMA; WEIGHT CONTROL;

CANCER VACCINES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; SELENIUM; VITAMIN E;

EID: 67650496219     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1750     Document Type: Review

References (331)

1. Le Clerc CG. The compleat surgeon. London: Walthos, Wilkin, Bonwicke and Ward; 1727.
2. Pott P. Cancer Scroti. In: Chirurgical observations relative to the cataract, the polypus of the nose, cancer of the scrotum, different kinds of ruptures, and the mortification of the toes and feet. London: Hawes, Clarke, Collins; 1775. p. 63-8.
3. LaMontagne AD, Christiani DC. Prevention of workrelated cancers (chapter 22). In: Colditz GA, Hunter D, editors. Cancer prevention: the causes and prevention of cancer. The Netherlands: Kluwer Academic Publishers; 2000. Vol. 1. p. 281-300.
4. Yamagiwa K, Ichikawa K. Experimental study of the pathgenesis of carcinoma. J Cancer Res 1918;3:1-21.
5. Cook JW, Hewett CL, Hieger I. The isolation of a cancer-producing hydrocarbon from coal tar. Parts I, II, and III. J Chem So (Resumed) 1933:395-405.
6. Récamier JCA. Recherches sur le traitment du cancer. Paris: Gabon; 1829.
7. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 1925; 42:753-77.
8. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-8.
9. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract-its etiology, manifestation, and significance. J Otolaryngol 1984;13:1-6.
10. Gazdar AF, Shames DS, Heda S. A global view of the field concept of carcinogenesis. Lancet Oncol. In press 2009.
11. Jang SJ, Chiba I, Hirai A, Hong WK, Mao L. Multiple oral squamous epithelial lesions: are they genetically related? Oncogene 2001;20:2235-42.
12. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
13. Kidd JG, Rous P. The carcinogenic effect of a papilloma virus on the tarred skin of rabbits. II. Major factors determining the phenomenon: the manifold effects of tarring. J Exp Med 1938;68:529-62.
14. Auerbach O, Forman JB, Gere JB, et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung; a report of progress. N Engl J Med 1957;256: 97-104.
15. Ames BN. Measuring oxidative damage in humans: relation to cancer and ageing. IARC Sci Publ 1988:407-16.
16. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chronic Dis 1982; 35:581-600.
17. Groopman JD, Kensler TW, Wild CP. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health 2008;29:187-203.
18. Weinstein IB, Jeffrey AM, Jennette KW, et al. Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo . Science 1976; 193:592-5.
19. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
20. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
21. Wattenberg LW. Chemoprophylaxis of carcinogenesis: a review. Cancer Res 1966;26:1520-6.
22. Berenblum I. The modifying influence of dichloroethyl sulphide on the induction of tumours in mice by tar. J Pathol Bacteriol 1929;SS:425-34.
23. Gelboin HV, Klein M, Bates RR. Inhibition of mouse skin tumorigenesis by actinomycin D. Proc Natl Acad Sci U S A 1965;53:1353-60.
24. Wattenberg L. Induction of increased benzpyrene detoxification in the lung. Federation Proc 1965;24:2027.
25. Wattenberg LW, Leong JL. Effects of phenothiazines on protective systems against polycyclic hydrocarbons. Cancer Res 1965;25:365-70.
26. Conney AH, Miller EC, Miller JA. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res 1956;16:450-9.
27. Benson AM, Batzinger RP, OuSY , Bueding E, Cha YN, Talalay P. Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo(α)pyrene by dietary antioxidants. Cancer Res 1978;38:4486-95.
28. Talalay P, Batzinger RP, Benson AM, Bueding E, Cha YN. Biochemical studies on the mechanisms by which dietary antioxidants suppress mutagenic activity. Adv Enzyme Regul 1978;17:23-36.
29. Chu EW, Malmgren RA. An inhibitory effect of vitamin A on the induction of tumors of forestomach and cervix in the Syrian hamster by carcinogenic polycyclic hydrocarbons. Cancer Res 1965;25:884-95.
30. Saffiotti U, Montesano R, Sellakumar AR, Borg SA. Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 1967;20:857-64.
31. Bollag W. Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumours. Int Z Vitaminforsch 1970;40:299-314.
32. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proc 1976; 35:1332-8.
33. Lips P. Hypervitaminosis A and fractures. N Engl J Med 2003;348:347-9.
34. Nataraja A. Man's best friend. BMJ 2002;10:131-70.
35. Bollag W. Vitamin A and retinoids: from nutrition to pharmacotherapy in dermatology and oncology. Lancet 1983;1:860-3.
36. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979;39: 1339-46.
37. Meyskens FL, Jr., Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-43.
38. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
39. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:949-56.
40. Hong WK, Endicott J, Itri LM, et al. 13-cis -Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
41. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamouscell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
42. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
43. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
44. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198-205.
45. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-10.
46. Lippman SM, Shin DM, Lee JJ, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;55:16-9.
47. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545-51.
48. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
49. Lotan R, XuXC, Lippman SM, et al. Suppression of retinoic acid receptor-h in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332:1405-10.
50. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with h-carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
51. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444-50.
52. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330:624-9.
53. Chemoprevention clinical trials: problems and solutions, NIH Publication No. 85-2715. Bethesda (MD): U.S. Department of Health and Human Services. November 1984.
54. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7.
55. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998;90:1514-28.
56. The effect of vitamin E and h-carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330: 1029-35.
57. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of h-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
58. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with h-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
59. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. h-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;91:2102-6.
60. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary hcarotene materially reduce human cancer rates? Nature 1981;290:201-8.
61. Gann PH. Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance-next, cause. JAMA 2009;301:102-3.
62. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
63. Kristal AR, Lippman SM. Nutritional prevention of cancer: new directions for an increasingly complex challenge. J Natl Cancer Inst 2009;101:363-5.
64. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
65. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
66. Yoshizawa S, Horiuchi T, Fujiki H, et al. Antitumor promoting activity of (-)-epigallocatechin gallate, the main constituent of "tannin" in green tea. Phytother Res 1987;1:44-7.
67. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988;48:5941-6.
68. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
69. Lee HY, Oh SH, Woo JK, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobaccoinduced lung tumorigenesis. J Natl Cancer Inst 2005;97: 1695-9.
70. Hecht SS, Kenney PM, Wang M, Upadhyaya P. Doseresponse study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo(α)pyrene. Cancer Lett 2001;167:1-6.
71. Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila Pa) 2009;2: 370-6.
72. Ambrosone CB, Tang L. Cruciferous vegetable intake and cancer prevention: role of nutrigenetics. Cancer Prev Res (Phila Pa) 2009;2:298-300.
73. Platz EA, Lippman SM. Selenium, genetic variation, and prostate cancer risk: Epidemiology reflects back on SELECT. J Clin Oncol. In press 2009.
74. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;148:104-7.
75. Lacassagne MA. Appearance of mammary cancers in male mice subjected to folliculin injections. Comptes Rendus de l'Academie des Sciences 1932;195:630-2.
76. Lacassagne A. Influence d'un facteur familial dans la production par la folliculine, de cancers mamaires chez la souris male. J Soc Biol 1933;114:427-9.
77. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 1966;55:1574-81.
78. Jordan VC. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974;5:354.
79. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
80. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
81. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc y716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87: 803-9.
82. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
83. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
84. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
85. Rideout WM, Coetze GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249: 1288-90.
86. Lapeyre JN, Becker FF. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem Biophys Res Commun 1979;87:698-705.
87. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
88. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-40.
89. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
90. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
91. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-9.
92. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-52.
93. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
94. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
95. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
96. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817-24.
97. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82.
98. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 2008;1:182-6.
99. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 2008;1:151-2.
100. Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa) 2008;1:167-73.
101. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
102. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a biasadjusted modeling approach. Cancer Prev Res (Phila Pa) 2008;1:174-81.
103. Andriole GL, Pettaway CA, TC, ILF, Somerville MC. Incidence of biopsy-detectable prostate cancer in the REduction of DUtasteride of Prostate Cancer Events (REDUCE) trial: Blinded 2-year results (abstract #2207). Presented at the Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, Illinois.
104. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-6.
105. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
106. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
107. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
108. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
109. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
110. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
111. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352: 1092-102.
112. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131: 1674-82.
113. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
114. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117:2104-13.
115. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Fiveyear efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2009;2:310-21.
116. Chan AT, Zauber AG, Hsu M, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009.
117. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1:32-8.
118. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77: 1309-13.
119. Sporn MB, Hong WK. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prev Res (Phila Pa) 2008;1:9-11.
120. Sporn MB. Combination chemoprevention of cancer. Nature 1980;287:107-8.
121. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Amer J Med Sc 1893;10:487-511.
122. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-94.
123. Pearl R. Cancer and tuberculosis. Am J Hyg 1929;9: 97-159.
124. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
125. Morales A. Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Cancer Immunol Immunother 1980;9:69-72.
126. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205-9.
127. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997;49:471-5.
128. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
129. Liaw Y-F, ChuC-M. Hepatitis B virus infection. Lancet 2009;373:582-92.
130. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967;66:924-31.
131. Blumberg BS, Larouze B, London WT, et al. The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am J Pathol 1975;81:669-82.
132. Ciuffo G. Innesto positivo con filtrato di verruca volgari. Jiorn Ital Mal Venereol 1907;48:12-7.
133. zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. Attempts to detect virus-secific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer 1974; 13:650-6.
134. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80:3812-5.
135. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
136. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.
137. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
138. Markowitz LE. HPV vaccines prophylactic, not therapeutic. JAMA 2007;298:805-6.
139. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
140. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
141. Blaser MJ. Understanding microbe-induced cancers. Cancer Prev Res (Phila Pa) 2008;1:15-20.
142. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-6.
143. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
144. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
145. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
146. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila Pa) 2008;1:308-11.
147. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55: 2111-5.
148. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 1990;58:603-10.
149. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
150. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
151. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987;257:796-800.
152. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
153. AntoniouA C, Rookus M, AndrieuN, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009;18:601-10.
154. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34.
155. Narod SA. Modifiers of risk of hereditary breast cancer. Oncogene 2006;25:5832-6.
156. Lathrop AEC, Loeb L. The influence of pregnancies on the incidence of cancer in mice. Proc Soc Exp Biol Med 1913;11:38-40.
157. Lathrop AE, Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res 1916;1:1-19.
158. Warthin AS. Heredity with reference to carcinoma. Arch Intern Med 1913;12:546-55.
159. Slye M. Cancer and heredity. Science 1916;43:135-6.
160. Boehme EJ. The surgical treatment of familial polyposis of the colon: a report of seven cases, six in one family. Ann Surg 1950;131:519-33.
161. Gardner CM. Polyposis of the colon. Arch Surg 1948; 56:75-8.
162. Warthin AS. The further study of a cancer family. J Cancer Res 1925;9:279-86.
163. Hauser IJ, Weller CV. A further report on the cancer family of Warthin. Am J Cancer 1936;27:434-49.
164. Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer 1971;27:1505-11.
165. Lynch HT, Harris RE, Organ CH, Jr., et al. The surgeon, genetics, and cancer control: the Cancer Family Syndrome. Ann Surg 1977;185:435-40.
166. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol 1982;59:589-96.
167. Lynch HT, Harris RE, Organ CH, Jr., Lynch JF. Management of familial breast cancer. I. Biostatisticalgenetic aspects and their limitations as derived from a familial breast cancer resource. Arch Surg 1978;113: 1053-8.
168. Lynch HT, Organ CH, Jr., Harris RE, Guirgis HA, Lynch PM, Lynch JF. Familial cancer: implications for surgical management of high-risk patients. Surgery 1978;83:104-13.
169. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820-3.
170. Knudson AG, Jr., Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972;48:313-24.
171. Knudson AG, Jr., Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972;24:514-32.
172. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72:975-83.
173. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
174. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA, Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-13.
175. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987;236:1100-2.
176. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75: 1027-38.
177. Hall JM, Lee MK, Newman B, et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
178. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
179. Leppert M, Dobbs M, Scambler P, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987;238:1411-3.
180. Douglas JA, Gruber SB, Meister KA, et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 2005;294:2195-202.
181. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
182. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
183. Kauff ND, Satagopan JM, Robson ME, et al. Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346: 1609-15.
184. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
185. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-9.
186. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340: 77-84.
187. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
188. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-17.
189. PapanicolaouGN. New cancer diagnosis. Proceedings of the Third Race Betterment Conference, January 2-6, 1928; 1928. p. 528-34.
190. Traut HF, Papanicolaou GN. Cancer of the uterus: the vaginal smear in its diagnosis. Cal West Med 1943;59: 121-2.
191. Quality assurance in cervical cytology. The Papanicolaousmear. Council on Scientific Affairs. JAMA 1989; 262:1672-9.
192. Gardner JW, Lyon JL. Efficacy of cervical cytologic screening in the control of cervical cancer. Prev Med 1977;6:487-99.
193. Johannesson G, Geirsson G, Day N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978; 21:418-25.
194. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987;1: 1247-9.
195. Schiffman M, Wacholder S. From India to the world-a better way to prevent cervical cancer. N Engl J Med 2009;360:1453-5.
196. Leborgne R. [Simple X-ray of diagnosis of breast tumors.]. Arch Urug Med Cir Espec 1950;37:44-9.
197. Leborgne R. Diagnosis of tumors of the breast by simple roentgenography; calcifications in carcinomas. Am J Roentgenol Radium Ther 1951;65:1-11.
198. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
199. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
200. Cameron AB, Thabet RJ. Sigmoidoscopy as part of routine cancer clinic examinations with correlated fecal chemistry and colon cytologic studies. Surgery 1960;48: 344-50.
201. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006;107:1624-33.
202. Wolff WI. Colonoscopy: history and development. Am J Gastroenterol 1989;84:1017-25.
203. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp StudyWorkgroup. N Engl J Med 1993;329: 1977-81.
204. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-11.
205. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
206. Van Lancker JL. Smoking and disease. NIDA Res Monogr 1977;230-88.
207. Weiss W, Benarde MA. The temporal relation between cigarette smoking and pancreatic cancer. Am J Public Health 1983;73:1403-4.
208. Greenwald P, Dunn BK. Landmarks in the history of cancer epidemiology. Cancer Res 2009;69:2151-62.
209. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950;2:739-48.
210. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J Am Med Assoc 1950; 143:329-36.
211. United States Surgeon General's Advisory Committee on Smoking and Health. Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. Department of Health, Education and Welfare, Public Health Service, Office of the Surgeon General 1964.
212. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC, Hoffmann D. Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst 1978; 60:819-24.
213. Ahmed PI, Gleeson GA. Changes in cigarette smoking habits between 1955 and 1966. Vital Health Stat 10 1970;10:1-33.
214. Wilson RW. Cigarette smoking and health characteristics. Vital Health Stat 10 1967;10:1-64.
215. Introduction, summary, overview and conclusions. In: The health consequences of smoking: nicotine addiction: a report of the Surgeon General. Center for Health Promotion and Education. Office on Smoking and Health; 1988. p. 1-20.
216. Blumer G. Irritants and radioactive substances as causes of cancer. Ann West Med Surg 1951;5:319.
217. Kosak AI. The composition of tobacco smoke. Experientia 1954;10:69-71.
218. Mills CA, Porter MM. Tobacco smoking habits and cancer of the mouth and respiratory system. Cancer Res 1950;10:539-42.
219. Schneider NG, Popek P, Jarvik ME, Gritz ER. The use of nicotine gum during cessation of smoking. Am J Psychiatry 1977;134:439-40.
220. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking-a study of male twins. N Engl J Med 1992;327:829-33.
221. Noble EP, St Jeor ST, Ritchie T, et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994;42:257-60.
222. Spitz MR, Shi H, Yang F, et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998;90:358-63.
223. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav 1983;8:253-61.
224. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008;53:1217-22.
225. Community Intervention Trial for Smoking Cessation (COMMIT). I. Cohort results from a four-year community intervention. Am J Public Health 1995;85:183-92.
226. Community intervention trial for smoking cessation (COMMIT). II. Changes in adult cigarette smoking prevalence. Am J Public Health 1995;85:193-200.
227. Stillman FA, Hartman AM, Graubard BI, Gilpin EA, Murray DM, Gibson JT. Evaluation of the American Stop Smoking Intervention Study (ASSIST): a report of outcomes. J Natl Cancer Inst 2003;95:1681-91.
228. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003;22:541-8.
229. Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002;12:627-34.
230. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976;2:1525-36.
231. Peto R, Lopez AD, Boreham J, Thun M, Heath C, Jr., Doll R. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
232. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.
233. Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Report No. EPA/600/6-90/006F. Washington (DC): Office of Health and Environmental Assessment, Office of Research and Development. 1992.
234. Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993;329:1543-6.
235. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008;21: 160-71.
236. IARC. "Tobacco smoke and involuntary smoking." Lyon (France): IARC; 2004. p. 1191-413.
237. U.S. Department of Health and Human Services. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Washington (DC): U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
238. National Institutes of Health. NIH State-of-the-Science Conference Statement on tobacco use: prevention, cessation, and control. NIH Consensus and State-of the-Science Statements 2006;23:1-26.
239. U.S. Department of Health, Education and Welfare. The health consequences of smoking for women: a report of the Surgeon General. Washington (DC): U.S. Department of Health, Education, and Welfare. Public Health Service, Office of the Assistant Secretary for Health; 1980.
240. Adler NE, Boyce T, Chesney MA, et al. Socioeconomic status and health. The challenge of the gradient. Am Psychol 1994;49:15-24.
241. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2005;54:625-8.
242. BarbeauE M, Krieger N, Soobader MJ. Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health 2004;94:269-78.
243. Hughes JR. The future of smoking cessation therapy in the United States. Addiction 1996;91:1797-802.
244. Wardle J, Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health 2003;57:440-3.
245. Frohlich KL, Potvin L. Transcending the known in public health practice: the inequality paradox: the population approach and vulnerable populations. Am J Public Health 2008;98:216-21.
246. Honjo K, Tsutsumi A, Kawachi I, Kawakami N. What accounts for the relationship between social class and smoking cessation? Results of a path analysis. Soc Sci Med 2006;62:317-28.
247. Satcher D. Overlooked and underserved: improving the health of men of color. Am J Public Health 2008;98: S139-41.
248. Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Understanding the associations among education, employment characteristics, and smoking. Addict Behav 2005;30:905-14.
249. Wetter DW, Mazas C, Daza P, et al. Reaching and treating Spanish-speaking smokers through the National Cancer Institute's Cancer Information Service. A randomized controlled trial. Cancer 2007;109:406-13.
250. Fiore MC, Croyle RT, Curry SJ, et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. Am J Public Health 2004;94:205-10.
251. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control 2006;15: 345-7.
252. Ending the tobacco problem - a blueprint for the nation. Institute of Medicine. Washington (DC): National Academies Press; 2007.
253. Farrelly MC, Davis KC, Haviland ML, Messeri P, Healton CG. Evidence of a dose-response relationship between "truth" antismoking ads and youth smoking prevalence. Am J Public Health 2005;95:425-31.
254. Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001;93:810-23.
255. Weiss SM, Schwartz GE. Behavioral medicine: the biobehavioral perspective. In: Surwit RS, Williams RB, Steptoe A, Biersner R, editors. Behavioral treatment of disease. New York (NY): Plenum; 1982.
256. Meissner HI, Smith RA, Rimer BK, et al. Promoting cancer screening: learning from experience. Cancer 2004;101:1107-17.
257. Pasick RJ, Hiatt RA, Paskett ED. Lessons learned from community-based cancer screening intervention research. Cancer 2004;101:1146-64.
258. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89:1406-22.
259. Lerman C, Croyle RT. Emotional and behavioral responses to genetic testing for susceptibility to cancer. Oncology (Huntingt) 1996;10:191-5, 9; discussion 200-2.
260. Kessler S, Jacopini AG. Psychological aspects of genetic counseling. II. Quantitative analysis of a transcript of a genetic counseling session. Am J Med Genet 1982;12:421-35.
261. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992;84:24-30.
262. Lerman C, Daly M, Sands C, et al. Mammography adherence and psychological distress among women at risk for breast cancer. J Natl Cancer Inst 1993;85:1074-80.
263. Wellisch DK, Gritz ER, Schain W, Wang HJ, SiauJ. Psychological functioning of daughters of breast cancer patients. Part II. Characterizing the distressed daughter of the breast cancer patient. Psychosomatics 1992;33: 171-9.
264. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 1997;16:63-72.
265. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
266. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 1994;154:609-16.
267. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993;269:1970-4.
268. Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2004;22:39-44.
269. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000;31:75-80.
270. Baumgartner RM. Body-composition studies. In: Spencer F, editor. History of physical anthropology: an encyclopedia. New York: Garland; 1997. Vol. 1. p. 190-5.
271. Quetelet LA. A treatise on man and the development of his faculties. 1842. Obes Res 1994;2:72-85.
272. Moreschi C. Bezuehungen zwischen ernahrung and tumorwachstum. Z fur Immunitatsforsch 1909;2:651-75.
273. Tannenbaum A. The initiation and growth of tumors. Introduction. 1. Effect of underfeeding. Am J Cancer 1940;38:335-50.
274. Tannenbaum A. The genesis and growth of tumors. II. Effects of caloric restriction per se. Cancer Res 1943;3: 749-56.
275. Visscher MB, Ball ZB, Barnes RH, Sivertsen I. The influence of caloric restriction upon the incidence of spontaneous mammary carcinoma in mice. Surgery 1942;11:48-55.
276. Vallejo EA. La dieta de hambre a dias altrenos en la alimentacion de los viejos. Rev Clin Esp 1956;63:25-8.
277. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-55.
278. Hurley LS. Nutrients and genes: interactions in development. Nutr Rev 1969;27:3-6.
279. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003;23:5293-300.
280. Thompson HJ. Effects of physical activity and exercise on experimentally induced mammary carcinogenesis. Breast Cancer Res Treat 1997;46:135-41.
281. Hursting SD. Mechanistic insights into reducing the weight of breast cancer. Cancer Prev Res (Phila Pa) 2009; 2:295-7.
282. Maimon SN, Palmer WL, Kirsner JB. The factors in 5 year survival of gastric cancer; a study of 30 cases. Proc Am Fed Clin Res 1947;3:10.
283. Demark-Wahnefried W, Jones LW. Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 2008;22:319-42, viii.
284. Rowland JH, Bellizzi KM. Cancer survivors and survivorship research: a reflection on today's successes and tomorrow's challenges. Hematol Oncol Clin North Am 2008;22:181-200, v.
285. Ganz PA. Current issues in cancer rehabilitation. Cancer 1990;65:742-51.
286. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-93.
287. de Waard F, RamlauR , Mulders Y, de Vries T, van Waveren S. A feasibility study on weight reduction in obese postmenopausal breast cancer patients. Eur J Cancer Prev 1993;2:233-8.
288. Chlebowski RT, Rose D, Buzzard IM, et al. Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS). Breast Cancer Res Treat 1992; 20:73-84.
289. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-76.
290. Courneya KS, Booth CM, Gill S, et al. The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol 2008;15:271-8.
291. Insull W, Jr., Henderson MM, Prentice RL, et al. Results of a randomized feasibility study of a low-fat diet. Arch Intern Med 1990;150:421-7.
292. Coates RJ, Bowen DJ, Kristal AR, et al. The Women's Health Trial Feasibility Study in Minority Populations: changes in dietary intakes. Am J Epidemiol 1999;149: 1104-12.
293. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
294. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-17.
295. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7; quiz 45.
296. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
297. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
298. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
299. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
300. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
301. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
302. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
303. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
304. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113: 2425-34.
305. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629-42.
306. Prentice RL, Thomson CA, Caan B, et al. Lowfat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007;99:1534-43.
307. Beresford SA, Johnson KC, Ritenbaugh C, et al. Lowfat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:643-54.
308. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
309. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008;100:1581-91.
310. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009;64:559-67.
311. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
312. DeVita VT, Jr., ChuE . A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
313. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
314. Gandhi L, McNamara KL, Li D, et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila Pa) 2009;2:330-7.
315. Grandis JR, Argiris A. Targeting angiogenesis from premalignancy to metastases. Cancer Prev Res (Phila Pa) 2009;2:291-4.
316. Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, Lingen MW. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila Pa) 2009;2: 385-93.
317. Dennis PA. Rapamycin for chemoprevention of upper aerodigestive tract cancers. Cancer Prev Res (Phila Pa) 2009;2:7-9.
318. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3¶-kinase/Akt pathway in vitro and in vivo . Cancer Res 2004;64:446-51.
319. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005;65:3226-35.
320. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2009;2:27-36.
321. Stoffel EM, Turgeon DK, Stockwell DH, et al. Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res (Phila Pa) 2008;1:507-13.
322. Kelloff GJ, Sigman CC, Contag CH. Early detection of oral neoplasia: watching with new eyes. Cancer Prev Res (Phila Pa) 2009;2:405-8.
323. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila Pa) 2009;2:423-31.
324. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid ( flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008;299:1027-35.
325. Hawk E, Guillem JG. Improving the vision of colonoscopy: does the fine print really matter? Cancer Prev Res (Phila Pa) 2008;1:495-8.
326. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7.
327. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-8.
328. Bhutani M, Pathak AK, Fan YH, et al. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila Pa) 2008;1:39-44.
329. Beane J, Sebastiani P, Whitfield TH, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila Pa) 2008;1:56-64.
330. Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila Pa) 2008;1:250-4.
331. Eliot TS. Tradition and the individual talent. Egoist 1919;6/4:54-5.